|
1
|
Onitilo AA, Engel JM, Greenlee RT and
Mukesh BN: Breast cancer subtypes based on ER/PR and Her2
expression: Comparison of clinicopathologic features and survival.
Clin Med Res. 7:4–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bauer KR, Brown M, Cress RD, Parise CA and
Caggiano V: Descriptive analysis of estrogen receptor
(ER)-negative, progesterone receptor (PR)-negative, and
HER2-negative invasive breast cancer, the so-called triple-negative
phenotype: A population-based study from the California cancer
registry. Cancer. 109:1721–1728. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dent R, Trudeau M, Pritchard KI, Hanna WM,
Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA:
Triple-negative breast cancer: Clinical features and patterns of
recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rakha EA, Elrehim DA, Paish C, Green AR,
Lee AH, Robertson JF, Blamey RW, Macmillan D and Ellis IO: Basal
phenotype identifes a poor prognostic subgroup of breast cancer of
clinical importance. Eur J Cancer. 42:3149–3156. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zaky SS, Lund MJ, May KA, Godette KD,
Beitler JJ, Holmes LR, O'Regan RM, Yu ES, Yu DS and Landry JC: The
negative effect of triple-negative breast cancer on outcome after
breast-conserving therapy. Ann Surg Oncol. 18:2858–2865. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fatica A and Bozzoni I: Long non-coding
RNAs: New players in cell differentiation and development. Nat Rev
Genet. 15:7–21. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Deva Magendhra Rao AK, Patel K, Korivi
Jyothiraj S, Meenakumari B, Sundersingh S, Sridevi V, Rajkumar T,
Pandey A, Chatterjee A, Gowda H and Mani S: Identification of
lncRNAs associated with early stage breast cancer and their
prognostic implications. Mol Oncol. 13:1342–1355. 2019.PubMed/NCBI
|
|
8
|
Chen X, Yan CC, Zhao X and You ZH: Long
non-coding RNAs and complex diseases: From experimental results to
computational models. Brief Bioinform. 18:558–576. 2017.PubMed/NCBI
|
|
9
|
Bertoli G, Cava C and Castiglioni I:
MicroRNAs: New biomarkers for diagnosis, prognosis, therapy
prediction and therapeutic tools for breast cancer. Theranostics.
5:1122–1143. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Haakensen VD, Nygaard V, Greger L, Aure
MR, Fromm B, Bukholm IR, Luders T, Chin SF, Git A, Caldas C, et al:
Subtype-specific micro-RNA expression signatures in breast cancer
progression. Int J Cancer. 139:1117–1128. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen X, Xie D, Zhao Q and You ZH:
Micrornas and complex diseases: From experimental results to
computational models. Brief Bioinform. 20:515–539. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Salmena L, Poliseno L, Tay Y, Kats L and
Pandolfi PP: A ceRNA hypothesis: The rosetta stone of a hidden RNA
language? Cell. 146:353–358. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
He R, Liu P, Xie X, Zhou Y, Liao Q, Xiong
W, Li X, Li G, Zeng Z and Tang H: circGFRA1 and GFRA1 act as ceRNAs
in triple negative breast cancer by regulating miR-34a. J Exp Clin
Cancer Res. 36:1452017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li S, Zhou J, Wang Z, Wang P, Gao X and
Wang Y: Long noncoding RNA GAS5 suppresses triple negative breast
cancer progression through inhibition of proliferation and invasion
by competitively binding miR-196a-5p. Biomed Pharmacother.
104:451–457. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Komatsu M, Yoshimaru T, Matsuo T, Kiyotani
K, Miyoshi Y, Tanahashi T, Rokutan K, Yamaguchi R, Saito A, Imoto
S, et al: Molecular features of triple negative breast cancer cells
by genome-wide gene expression profiling analysis. Int J Oncol.
42:478–506. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mathe A, Wong-Brown M, Morten B, Forbes
JF, Braye SG, Avery-Kiejda KA and Scott RJ: Novel genes associated
with lymph node metastasis in triple negative breast cancer. Sci
Rep. 5:158322015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu YR, Jiang YZ, Xu XE, Hu X, Yu KD and
Shao ZM: Comprehensive transcriptome profiling reveals multigene
signatures in triple-negative breast cancer. Clin Cancer Res.
22:1653–1662. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Romero-Cordoba SL, Rodriguez-Cuevas S,
Bautista-Pina V, Maffuz-Aziz A, D'Ippolito E, Cosentino G, Baroni
S, Iorio MV and Hidalgo-Miranda A: Loss of function of miR-342-3p
results in MCT1 over-expression and contributes to oncogenic
metabolic reprogramming in triple negative breast cancer. Sci Rep.
8:122522018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Varley KE, Gertz J, Roberts BS, Davis NS,
Bowling KM, Kirby MK, Nesmith AS, Oliver PG, Grizzle WE, Forero A,
et al: Recurrent read-through fusion transcripts in breast cancer.
Breast Cancer Res Treat. 146:287–297. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Moradifard S, Hoseinbeyki M, Ganji SM and
Minuchehr Z: Analysis of microRNA and gene expression profiles in
Alzheimer's disease: A meta analysis approach. Sci Rep. 8:47672018.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: Limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kolde R, Laur S, Adler P and Vilo J:
Robust rank aggregation for gene list integration and
meta-analysis. Bioinformatics. 28:573–580. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shi KQ, Lin Z, Chen XJ, Song M, Wang YQ,
Cai YJ, Yang NB, Zheng MH, Dong JZ, Zhang L and Chen YP:
Hepatocellular carcinoma associated microRNA expression signature:
Integrated bioinformatics analysis, experimental validation and
clinical significance. Oncotarget. 6:25093–25108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang J, Han S, Huang W, Chen T, Liu Y, Pan
S and Li S: A meta-analysis of microRNA expression in liver cancer.
PLoS One. 9:e1145332014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Huang da W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Szklarczyk D, Morris JH, Cook H, Kuhn M,
Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, et al:
The STRING database in 2017: Quality-controlled protein-protein
association networks, made broadly accessible. Nucleic Acids Res.
45:D362–D368. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Perou CM, Sørlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–752. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sørlie T, Perou CM, Tibshirani R, Aas T,
Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey
SS, et al: Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implications. Proc Natl
Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sorlie T, Tibshirani R, Parker J, Hastie
T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et
al: Repeated observation of breast tumor subtypes in independent
gene expression data sets. Proc Natl Acad Sci USA. 100:8418–8423.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Prat A, Parker JS, Karginova O, Fan C,
Livasy C, Herschkowitz JI, He X and Perou CM: Phenotypic and
molecular characterization of the claudin-low intrinsic subtype of
breast cancer. Breast Cancer Res. 12:R682010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Blows FM, Driver KE, Schmidt MK, Broeks A,
van Leeuwen FE, Wesseling J, Cheang MC, Gelmon K, Nielsen TO,
Blomqvist C, et al: Subtyping of breast cancer by
immunohistochemistry to investigate a relationship between subtype
and short and long term survival: A collaborative analysis of data
for 10,159 cases from 12 studies. PLoS Med. 7:e10002792010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Carey LA, Perou CM, Livasy CA, Dressler
LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S,
et al: Race, breast cancer subtypes, and survival in the carolina
breast cancer study. JAMA. 295:2492–2502. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Long J, Bai Y, Yang X, Lin J, Yang X, Wang
D, He L, Zheng Y and Zhao H: Construction and comprehensive
analysis of a ceRNA network to reveal potential prognostic
biomarkers for hepatocellular carcinoma. Cancer Cell Int.
19:902019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang X, Zhang W, Jiang Y, Liu K, Ran L
and Song F: Identification of functional lncRNAs in gastric cancer
by integrative analysis of GEO and TCGA data. J Cell Biochem.
120:17898–17911. 2019.PubMed/NCBI
|
|
36
|
Wang X, Ding Y, Da B, Fei Y and Feng G:
Identification of potential prognostic long non-coding RNA
signatures based on a competing endogenous RNA network in lung
adenocarcinoma. Oncol Rep. 40:3199–3212. 2018.PubMed/NCBI
|
|
37
|
Zhu H, Dai M, Chen X, Chen X, Qin S and
Dai S: Integrated analysis of the potential roles of miRNA-mRNA
networks in triple negative breast cancer. Mol Med Rep.
16:1139–1146. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yang R, Xing L, Wang M, Chi H, Zhang L and
Chen J: Comprehensive analysis of differentially expressed profiles
of lncRNAs/mRNAs and miRNAs with associated cerna networks in
triple-negative breast cancer. Cell Physiol Biochem. 50:473–488.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yuan N, Zhang G, Bie F, Ma M, Ma Y, Jiang
X, Wang Y and Hao X: Integrative analysis of lncRNAs and miRNAs
with coding RNAs associated with ceRNA crosstalk network in triple
negative breast cancer. Onco Targets Ther. 10:5883–5897. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Võsa U, Kolde R, Vilo J, Metspalu A and
Annilo T: Comprehensive meta-analysis of microrna expression using
a robust rank aggregation approach. Methods Mol Biol. 1182:361–373.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Cheang MC, Chia SK, Voduc D, Gao D, Leung
S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, et al: Ki67
index, HER2 status, and prognosis of patients with luminal B breast
cancer. J Natl Cancer Inst. 101:736–750. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ali HR, Dawson SJ, Blows FM, Provenzano E,
Pharoah PD and Caldas C: Aurora kinase A outperforms Ki67 as a
prognostic marker in ER-positive breast cancer. Br J Cancer.
106:1798–1806. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Dawson SJ, Makretsov N, Blows FM, Driver
KE, Provenzano E, Le Quesne J, Baglietto L, Severi G, Giles GG,
McLean CA, et al: BCL2 in breast cancer: A favourable prognostic
marker across molecular subtypes and independent of adjuvant
therapy received. Br J Cancer. 103:668–675. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chen X and Huang L: LRSSLMDA: Laplacian
regularized sparse subspace learning for miRNA-disease association
prediction. PLoS Comput Biol. 13:e10059122017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chen X, Yin J, Qu J and Huang L: MDHGI:
Matrix decomposition and heterogeneous graph inference for
miRNA-disease association prediction. PLoS Comput Biol.
14:e10064182018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chen X, Wang L, Qu J, Guan NN and Li JQ:
Predicting miRNA-disease association based on inductive matrix
completion. Bioinformatics. 34:4256–4265. 2018.PubMed/NCBI
|
|
47
|
Chen X, Zhu CC and Yin J: Ensemble of
decision tree reveals potential miRNA-disease associations. PLoS
Comput Biol. 15:e10072092019. View Article : Google Scholar : PubMed/NCBI
|
